Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.93 |
| ▸ | AXL | P30530 | 14/20 | 0.88 |
| ▸ | MERTK | Q12866 | 3/20 | 0.88 |
| ▸ | FLT1 | P17948 | 3/20 | 0.88 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.88 |
| ▸ | AURKA | O14965 | 1/20 | 0.88 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.88 |
| ▸ | ABL1 | P00519 | 1/20 | 0.88 |
| ▸ | EGFR | P00533 | 1/20 | 0.88 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.88 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.88 |
| ▸ | LCK | P06239 | 1/20 | 0.88 |
| ▸ | PGR | P06401 | 1/20 | 0.88 |
| ▸ | LYN | P07948 | 1/20 | 0.88 |
| ▸ | RET | P07949 | 1/20 | 0.88 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.88 |
| ▸ | HCK | P08631 | 1/20 | 0.88 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.88 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16083190 | 0.96 | MET (1.00) | METAXLMERTKFLT1AURKB | |
| Cabozantinib SCHEMBL29728791 | 0.93 | AXL (1.00) | METAXLMERTKFLT1AURKB | |
| Cabozantinib SCHEMBL360795 | 0.93 | AXL (1.00) | METAXLMERTKFLT1AURKB | |
| Cabozantinib SCHEMBL29351408 | 0.93 | AXL (1.00) | METAXLMERTKFLT1AURKB | |
| Cabozantinib SCHEMBL18095042 | 0.93 | AXL (0.98) | METAXLMERTKFLT1AURKB | |
| SCHEMBL24556966 | 0.91 | AXL (0.88) | METAXLMERTKFLT1AURKB | |
| Cabozantinib SCHEMBL18097906 | 0.91 | AXL (0.94) | METAXLMERTKFLT1AURKB | |
| SCHEMBL16083191 | 0.91 | AURKB (0.87) | METAXLMERTKFLT1AURKB | |
| SCHEMBL29693516 | 0.90 | AXL (0.88) | METAXLMERTKFLT1AURKB | |
| SCHEMBL4401190 | 0.90 | AXL (0.88) | METAXLMERTKFLT1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | ANGEX PHARMACEUTICAL, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220162184-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| EP-3950677-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | Primegene (Beijing) Co., Ltd. (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-20210163445-A1 | CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210002228-A1 | Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2020200160-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 北京国鸿生物医药科技有限公司 | 2020-10-08 | — | — | WO | disclosed |
| US-20200255382-A1 | Method of Treating Cancer and Bone Cancer Pain | EXELIXIS, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200163954-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190218182-A1 | Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-10273211-B2 | Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190076420-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20160031818-A1 | Metabolites of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2016-02-04 | — | — | US | disclosed |
| WO-2015142928-A1 | DOSING OF CABOZANTINIB FORMULATIONS | EXELIXIS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2014145715-A1 | METABOLITES OF N-(4-{[6,7-BIS(METHYLOXY)QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE | EXELIXIS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | MET, ABL1, KRAS | MET 1/4885AXL 169/4885MERTK 140/4885 |
| US-20200255382-A1 | Method of Treating Cancer and Bone Cancer Pain | TPO, OGFR, CALCR | MET 78/4885AXL 3057/4885MERTK 2208/4885 |
| US-20190076420-A1 | Dosing of Cabozantinib Formulations | MET, ABL1, KRAS | MET 1/4885AXL 169/4885MERTK 140/4885 |
| US-20220162184-A1 | QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF | HDAC11, HDAC1, HDAC6 | MET 579/4885AXL 1078/4885MERTK 1369/4885 |
| US-20210002228-A1 | Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | NQO2, AURKA, CDC25B | MET 369/4885AXL 1280/4885MERTK 2348/4885 |
| US-20200163954-A1 | Dosing of Cabozantinib Formulations | MET, ABL1, KRAS | MET 1/4885AXL 169/4885MERTK 140/4885 |
| US-10273211-B2 | Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | NQO2, AURKA, CDC25A | MET 380/4885AXL 1354/4885MERTK 2336/4885 |
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | UCK2, ULK2, CDK9 | MET 1893/4885AXL 437/4885MERTK 309/4885 |
| US-20190218182-A1 | Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | NQO2, AURKA, CDC25B | MET 369/4885AXL 1280/4885MERTK 2348/4885 |
| US-20210163445-A1 | CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS | UCK2, ULK2, CDK9 | MET 1893/4885AXL 437/4885MERTK 309/4885 |
| US-20160031818-A1 | Metabolites of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | IDH1, NTRK3, FGFR4 | MET 261/4885AXL 1634/4885MERTK 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.